Henan Tongwei Medical Equipment Co., LtdCall us : +86 − −19139704654 // Email us : [email protected]

MENU China Mining Equipment Industry & Technology Group Co., Ltd.
  • Home
  • Products
  • About
  • Contact

Home / Products

structure-based design of antiviral drug candidates

  • Microorganisms

    Structure-based drug design is key to antiviral development The available cocrystal structures of SARS-CoV-2 3CL pro with different types of inhibitors are critical for improving the potency and understanding the mode of action of inhibitors This approach is also important in fragment-based drug design by providing efficient strategies for

    Get Price
  • Structure Based Drug Design

    Structure-based design of antiviral drug candidates Fragment-based drug discovery is a strategy widely used in both academia and pharmaceutical companies to generate small-molecule protein inhibitors and drug candidates Among the approaches reported in the literature (growing linking and merging) the linking approach

    Get Price
  • Novel Compounds Designed To Inhibit SARS

    Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease SARS-CoV-2 is the etiological agent responsible for the global COVID-19 outbreak The main protease (Mpro) of SARS-CoV-2 is a key enzyme that plays a pivotal role in mediating viral replication and transcription

    Get Price
  • Research progress on repositioning drugs and specific

    Jul 08 2020In this review we provide an overview of published scientific information about small molecular anti-SARS-CoV-2 drugs with an emphasis on repositioning antiviral drugs and the novel SARS-CoV-2 specific antiviral drugs for COVID-19

    Get Price
  • 3C

    The protease 3CLpro is a potential drug target for coronavirus infections due to its essential role in processing the polyproteins that are translated from the viral RNA The X-ray structures of the unliganded SARS-CoV-2 protease 3CLpro and its complex with an α-ketoamide inhibitor provides a basis for design of α-ketoamide inhibitors [6] for

    Get Price
  • (KMS): Structure

    Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease: Wenhao Dai Bing Zhang Xia-Ming Jiang Haixia Su Jian Li Yao Zhao 3 Xiong Xie Zhenming Jin Jingjing Peng Fengjiang Liu Chunpu Li You Li Fang Bai Haofeng Wang Xi Cheng Xiaobo Cen Shulei Hu Xiuna Yang Jiang Wang Xiang Liu Gengfu Xiao Hualiang Jiang Zihe Rao Lei-Ke Zhang

    Get Price
  • Structure Based Drug Design

    Structure-based design of antiviral drug candidates Fragment-based drug discovery is a strategy widely used in both academia and pharmaceutical companies to generate small-molecule protein inhibitors and drug candidates Among the approaches reported in the literature (growing linking and merging) the linking approach

    Get Price
  • Targeting the Dimerization of the Main Protease of

    May 13 2020A new coronavirus (CoV) caused a pandemic named COVID-19 which has become a global health care emergency in the present time The virus is referred to as SARS-CoV-2 (severe acute respiratory syndrome-coronavirus-2) and has a genome similar (∼82%) to that of the previously known SARS-CoV (SARS coronavirus) An attractive therapeutic target for CoVs is the main protease (Mpro)

    Get Price
  • Lead Optimization for the Antiviral Drug Discovery of

    The higher the quality of preclinical drug candidates the higher the likelihood of successful entry into clinical development Creative Biostructure provides a comprehensive set of structure-based services for the discovery of antiviral agents for treatment of coronavirus infection If you have research needs for optimization of antiviral

    Get Price
  • Lead Optimization for the Antiviral Drug Discovery of

    The higher the quality of preclinical drug candidates the higher the likelihood of successful entry into clinical development Creative Biostructure provides a comprehensive set of structure-based services for the discovery of antiviral agents for treatment of coronavirus infection If you have research needs for optimization of antiviral

    Get Price
  • How structural biology is playing a role to tackle COVID

    May 27 2020Zhang L et al 2020 Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors Science doi: 10 1126/science abb3405 Dai W et al 2020 Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease Science doi: 10 1126 science abb4489 Gao Y et al 2020

    Get Price
  • Genomics insights of SARS

    Jul 31 2020Coronavirus disease (COVID-19) pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) COVID-19 is a global health emergency and no clinically approved vaccines or antiviral drugs available to date Intensive research on SARS-CoV-2 is urgently warranted to understand its pathogenesis and virulence mechanisms and to discover target-based antiviral

    Get Price
  • Structure

    Mar 26 2020Structure-Based Design of Antivirals against Envelope Glycoprotein of Dengue Virus None of the current DENV antiviral candidates possess potency similar to the approved antiviral drugs which indicates that more efforts and resources must be invested before an effective DENV drug

    Get Price
  • Cyanohydrin as an Anchoring Group for Potent and Selective

    Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease Science 2020 eabb4489 DOI: 10 1126/science abb4489 Rafael Pinto Vieira Viviane Corra Santos Rafaela Salgado Ferreira Structure-based Approaches Targeting Parasite Cysteine Proteases

    Get Price
  • Regulatory updates on China April 2020

    May 04 2020Structure-Based Design of Antiviral Drug Candidates Targets SARS-CoV-2 Main Protease A team of Chinese scientists recently developed two novel compounds that inhibit the SARS-CoV-2 main protease (Mpro) and one of them is a drug candidate for further clinical studies The research published online in Science on 22 April 2020 was conducted by

    Get Price
  • Structure

    Apr 22 2020Structure-based design of antiviral drug candidates targets SARS-CoV-2 main protease April 22 2020 A team of Chinese scientists has recently developed two novel compounds that inhibit the SARS-CoV-2 main protease (M pro) and one of them is a good drug candidate for further clinical studies The research published online in Science on April 22 was conducted by Prof LIU

    Get Price
  • Structure

    Structure-based drug design approach: Screening of ChEMBL antiviral compounds We have screened the ChEMBL database for antiviral drugs that have passed the Lipinski's rule of five (RO5) for drug-likeliness The structure-based drug design approach was taken into consideration using both the S protein and the M pro of SARS-CoV-2 The

    Get Price
  • Recent insights for the emerging COVID

    Jul 04 2020Dai and coworkers had conducted the structure-based design of antiviral agents targeting this protease by parsing out the substrate-binding pocket of M pro In this regard further study targeting such a protease may give rise to certain antiviral drug candidates

    Get Price
  • Structure

    Mar 25 2020Structure-Based Design Synthesis and Biological Evaluation of Peptidomimetic Aldehydes as a Novel Series of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease Wenhao Dai a d † Bing Zhang b † Xia-Ming Jiangc † Haixia Su a † Jian Li a Yao Zhao

    Get Price
  • Structure

    Structure-based design of antiviral drug candidates targets SARS-CoV-2 main protease 04-22-2020 Comments Off on Structure-based design of antiviral drug candidates targets SARS-CoV-2 main protease A team of Chinese scientists has recently developed two novel compounds that inhibit the SARS-CoV-2 main protease (M pro ) and one of them is a good

    Get Price
  • Structure

    Apr 22 2020Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease Wenhao Dai 1 2 * Bing Zhang 4 * Haixia Su 1 * Jian Li 1 5 Yao Zhao 3 Xiong Xie 1 Zhenming Jin 1 Fengjiang Liu 3 Chunpu Li 1 You Li 6 Fang Bai 3 Haofeng Wang 3 Xi Cheng 1 Xiaobo Cen 6 Shulei Hu 1 Xiuna Yang 3 Jiang Wang

    Get Price
  • Recent insights for the emerging COVID

    Jul 04 2020Dai and coworkers had conducted the structure-based design of antiviral agents targeting this protease by parsing out the substrate-binding pocket of M pro In this regard further study targeting such a protease may give rise to certain antiviral drug candidates

    Get Price
  • Cocrystal Pharma Inc 's Structure

    The Company is currently leveraging its unique structure-based technologies to develop antiviral drugs for hepatitis C influenza and norovirus Influenza Program To date Cocrystal's lead influenza molecule in development CC-42344 has shown excellent antiviral activity against influenza A strains including avian pandemic strains and

    Get Price
  • COVID/SARS CoV2 Rapid Research Reports #3 (Virtual)

    Hong Liu Chinese Academy of Sciences Shanghai - Structure-based Design of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease Yogesh Gupta University of Texas San Antonio - Structural Basis of RNA Cap Modification by SARS-CoV-2 Coronavirus

    Get Price
  • Structure

    This study shows that structure-based drug design is an effective strategy for designing specific antiviral leads against SARS-CoV-2 Preclinical research on compound 11a is now proceeding The team has decided to share its research data with scientists around the world to accelerate the development of anti-SARS-CoV-2 drugs

    Get Price
  • Structure

    Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease Wenhao Dai 1 2 * Bing Zhang 4 * Haixia Su 1 * Jian Li 1 5 Yao Zhao 3 Xiong Xie 1 Zhenming Jin 1 Fengjiang Liu 3 Chunpu Li 1 You Li 6 Fang Bai 3 Haofeng Wang 3 Xi Cheng 1 Xiaobo Cen 6 Shulei Hu 1 Xiuna Yang 3 Jiang Wang

    Get Price
  • Structure

    Mar 26 2020Structure-Based Design of Antivirals against Envelope Glycoprotein of Dengue Virus None of the current DENV antiviral candidates possess potency similar to the approved antiviral drugs which indicates that more efforts and resources must be invested before an effective DENV drug

    Get Price
  • 'Flu' and structure

    The drug design goal therefore has been to develop potent NA inhibitors first by random screening then by mechanistic design of transition state analogues and most recently by SBDD Figure 1 Schematic diagram showing the chronology of the main steps in the design

    Get Price
  • china wholesale disposable non woven anti-slip

    ge logiq e bt12 portable ultrasound system user

    sundstrm sr100 half face respirator - rsea

    3d printing face shields for canadian medical teams

    automatic pepper spice powder packing machine

    bausteine strukturierte textwiedergabe

    security services - golden svcs

    plastic bottles and containers for pharmaceuticals -

    hunter education courses online - homestead

    china italy design hot sale fashion frame tr90

    respiratory protection series - hubei juya protective

    non-invasive quality evaluation of confluent cells by

    injection molding guide - lubrizol

    8210v respirator san marino - surgical face mask

    2020 wilson for sale - dinnerware collectibles

    big bag for sale from china suppliers

    packaging innovations for medical wearables - the

    powerful stretch mark anti aging cream reviews

    schwarzer bildschirm der iphone kamera nach dem

    china laminated pp spunbond non-woven fabric -

    ppe coverall - garments and apparel manufacturers and

    abc news - surgeon general shows how to make

    face mask face cover 3d cone shape quilters

    termometr braun thermoscan pro 6000 welch allyn

    china disposable non-woven face mask ear-loop or

    carola norcia - interpreter and translator -

    china best selling high speed automatic mask

    hospital nurse uniform ww2 medical supply - buy

Henan Tongwei

Henan Tongwei Medical Device Co., Ltd. is a branch company of Guangzhou Ningwei Technology Co., LTD., which is specialized in the production, processing, sales, research and development and service of related products and equipment in the medical device industry.

Contact Us

  • : Room 810, Block B, Jinzhonghuan Building, Zhengzhou City, Henan Province
  • : +86 19139704654
  • : [email protected]

products

NIOSH N95

Mask Machine

hospital doctor safety ppe coverall medical protection suit with hood

BFE99 Melt Blown Fabric

surgical gown aami level 3

7/24 | Online | Chat | Now TONGWEIMEDICAL © All Rights Reserved.